Senate health committee to hold hearing on Trump drug pricing plan

Senate health committee to hold hearing on Trump drug pricing plan
© Greg Nash

President TrumpDonald John TrumpCNN's Camerota clashes with Trump's immigration head over president's tweet LA Times editorial board labels Trump 'Bigot-in-Chief' Trump complains of 'fake polls' after surveys show him trailing multiple Democratic candidates MORE's top health official will testify at a Senate hearing next month about the president’s proposal to reduce prescription drug costs.

Health and Human Services Secretary Alex Azar will testify at the June 12 Senate Health, Education, Labor and Pensions Committee hearing, the first time lawmakers will publicly examine Trump’s plan, which was unveiled earlier this month.

Committee Chairman Lamar AlexanderAndrew (Lamar) Lamar AlexanderThe Hill's Morning Report - Presented by JUUL Labs - Trump attack on progressive Dems draws sharp rebuke Republicans make U-turn on health care Trump announces, endorses ambassador to Japan's Tennessee Senate bid MORE (R-Tenn.) did not indicate whether the hearing will result in legislation.

According to Trump, the administration can tackle many of the proposals on its own. But some more significant changes — like how Medicare pays for drugs — could require Congress.

Democrats have attacked Trump’s proposals for not going far enough. For example, his plan does not include a call for Medicare to negotiate drug prices directly.

Separately, House Ways and Means Committee Chairman Kevin BradyKevin Patrick BradyLawmakers join Nats Park fundraiser for DC kids charity On The Money: Fed chief hints strongly at rate cut | Powell lays out 'serious concerns' over Facebook crypto project | Trump official to investigate French tech tax | Acosta defends Epstein deal Trump administration launches investigation into French plan for tax on tech giants MORE (R-Texas) said last week that he also intends to hold hearings on Trump’s drug pricing plan.

Most observers don’t expect Congress to take major action on a contentious issue like drug prices in an election year, but the hearings indicate there could at least be some discussion of the issue in Congress.